Li-Fraumeni syndrome (LFS) is an autosomal-dominant cancer predisposition disorder associated with pathogenic germline variants in TP53, with a high penetrance over an individual's lifetime. The actual population prevalence of pathogenic germline TP53 mutations is still unclear, most likely due to biased selection of cancer affected families. The aim of this study was to estimate the population prevalence of potentially pathogenic TP53 exonic variants in three sequencing databases, totaling 63,983 unrelated individuals. Potential pathogenicity was defined using an original algorithm combining bioinformatic prediction tools, suggested clinical significance, and functional data. We identified 34 different potentially pathogenic TP53 variants in 131 out of 63,983 individuals (0.2%). Twenty-eight (82%) of these variants fell within the DNA-binding domain of TP53, with an enrichment for specific variants that were not previously identified as LFS mutation hotspots, such as the p.R290H and p.N235S variants. Our findings reveal that the population prevalence of potentially pathogenic TP53 variants may be up to 10 times higher than previously estimated from family-based studies. These results point to the need for further studies aimed at evaluating cancer penetrance modifiers as well as the risk associated between cancer and rare TP53 variants.
INTRODUCTION
) is an autosomaldominant cancer predisposition disorder (Li & Fraumeni, 1969a,b) associated with germline TP53 (MIM# 191170) mutations (Malkin et al., 1990) . Several clinical definitions based on familial and individual tumor history have been proposed (Birch et al., 1994; Bougeard et al., 2015; Eeles, 1995; Li & Fraumeni, 1969a; Li & Fraumeni, 1969b) . The core LFS tumor spectrum is dominated by pre-menopausal breast carcinomas and soft-tissue sarcomas in adults, and by brain cancer and adrenocortical carcinomas in children (Bougeard et al., 2015) .
The penetrance of cancer is highly variable and associated, at least in part, with the structural and functional effect of the causative TP53 variant (Olivier, Hollstein, & Hainaut, 2010) . Nevertheless, most studies consistently report that about 50% of the carriers develop at least one malignancy by 30-40 years of age, with a lifetime penetrance of about 90% (Mai et al., 2016; Malkin, 2011) . Population prevalence estimates of pathogenic germline TP53 variants range from one in 5,000 (Lalloo et al., 2003) to one in 20,000 (Gonzalez et al., 2009) individuals; however, these observational studies were based on participants selected on personal and familial cancer history.
Large-scale next-generation sequencing (NGS) has generated databases such as the Exome Aggregation Consortium (ExAC) (Lek et al., 2016 ) that contain extensive catalogues of genetic variations across different populations unselected for specific disease traits. To provide population estimates, we have analyzed the prevalence of potentially pathogenic TP53 variants in three aggregated datasets composed of 63,983 individuals unselected for personal or familial cancer history.
METHODS

Populations included
We evaluated TP53 sequencing data from three pooled datasets of unrelated, adult study participants: (1) 53,105 individuals (median age and range not available) from 13 studies included in the ExAC database (https://exac.broadinstitute.org/about) (Lek et al., 2016) , excluding individuals selected due to cancer history who were part of The Cancer Genome Atlas Research Network database (TCGA, https://cancergenome.nih.gov/); (2) 9,884 women from the Fabulous Ladies Over Seventy database (FLOSSIES, https://whi.color.com/), over the age of 70 years (median age = 80, range 70-99) without a personal history of cancer; and (3) 994 cancer-free individuals (median age = 68, range 37-88) who underwent exome sequencing as part of three distinct cancer population-based studies:
Environment And Genetics in Lung Cancer Etiology -(EAGLE) (Landi et al., 2008) ; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (Prorok et al., 2000) and Cancer Prevention Study II (CPSII) (Calle et al., 2002) . The combination of these cohorts will be hereafter referenced as whole-exome sequencing controls (WES Controls). A schematic representation of database selection is shown in Figure 1 .
Annotations on ethnicity were reported as described in the original ExAC and FLOSSIES databases. Our analysis included all the ancestries reported in these databases. Single-nucleotide polymorphism array data were previously used to determine that all individuals were of European ancestry in the EAGLE, PLCO, and CPS-II datasets (Savage et al., 2013) .
Variant filtering and classification
Parameters used for variants filtering are shown in Figure 1 . Briefly, variants detected and reported in the three databases were annotated using ANNOVAR (Wang, Li, & Hakonarson, 2010) , and selected considering TP53 gene region reported as exonic by the RefGene database, and with minor allele frequency (MAF) less than 0.01 in the ExAC non-TCGA database (Lek et al., 2016) . Variants were filtered and interpreted based on the canonical transcript NM_000546.5 (nucleotide numbering for cDNA uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1) to allow cross referencing with the International Agency for
Research on Cancer (IARC) TP53 variant database, which compiles information on variants identified in subjects with LFS or LFS-like profiles described in the literature (Bouaoun et al., 2016) . Multi-allelic, intronic, and UTR variants were not included in this analysis. Variants were further annotated using the VEP dbscSNV plugin (Jian, Boerwinkle, & Liu, 2014) to predict splice-site variants. There was no variant predicted to affect TP53 splice donor/acceptor sites in the canonical transcript (NM_000546.5). According to the RefGene database, these variants were annotated as either exonic or intronic and interpreted based on our filtering/classification scheme ( Figure 1 and Table 1, respectively).
For variant classification, we adapted the guidelines proposed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (Richards et al., 2015) . Variants were classified as pathogenic (P), likely pathogenic (LP), possibly pathogenic (PP), likely benign (LB), and uncertain significance (VUS) based on the parameters and rules defined in Table 1 . Essentially, we used three main criteria: (1) REVEL score with a threshold set to greater than 0.5, which yields a sensitivity of 0.754 and specificity of 0.891 when predicting disease mutations (Ioannidis et al., 2016) ; (2) Clinical significance evidences provided by either ClinVarversion 2017013 (Landrum et al., 2016) or The Human Gene Mutation Database (HGMD) (Stenson et al., 2014) ; and (3) Transcriptional activity based on a yeast-based functional assay (Kato et al., 2003) compiled in the IARC database of TP53 variants-version R18 April 2016 (Bouaoun et al., 2016) .
For analysis purposes, the combination of pathogenic and likely pathogenic categories will be hereafter denominated as potentially pathogenic.
Statistical analysis
Fisher's exact tests were performed to compare the proportions of TP53 variants carrier individuals between different ethnic ancestries.
F I G U R E 1
Flowchart with a summary of parameters used for variants selection and filtering. Our analysis is based on a pooled dataset composed by 63,983 individuals, after excluding the TCGA dataset from the ExAC consortium. Variants were annotated using ANNOVAR and selected based on gene region equivalent to exonic and with MAF < 0.01. The canonical transcript NM_00546.5 was used as sequence reference for gene region location based on the RefGene database. Abbreviations: TCGA, The Cancer Genome Atlas; ExAC, Exome Aggregation Consortium; FLOSSIES, Fabulous Ladies Over Seventy; WES, whole-exome sequencing; MAF, minor allele frequency.
TA B L E 1 Criteria for TP53 variants classification
Variant category
Bioinformatics Clinical significance Functional assay
Variant classification
Missense or nonsense Silent REVEL > 0.5 HGMD = DM or ClinVar = P/LP Non-functional Functional
Variants were classified as pathogenic, likely pathogenic, possibly pathogenic, likely benign, or with uncertain significance based on three main parameters: REVEL score (threshold set to greater than 0.5), clinical significance evidences provided by HGMD and ClinVar (at least one entry supporting pathogenic or likely pathogenic classification), and transcriptional activity. Check marks represent that the variant must meet the requirement. Cross marks represent that the variant must not meet the requirement. 
RESULTS
Prevalence of potentially pathogenic TP53 variants in the ExAC non-TCGA database
A total of 142 unique TP53 variants with MAF < 1% were detected in the ExAC non-TCGA database (N = 53,105), including 84 non-synonymous, 56 synonymous, one nonsense, and one nonframeshift deletion. From these, 17 were classified as P, 13 as LP, 22 as PP, 83 as LB, and 7 as VUS. Based on the allele count values for P only or in combination with the allele counts for P and LP, the prevalence of germline TP53 variants in this database ranged from 0.06% to 0.21% (Table 2) . Out of 111 individuals carrying potentially pathogenic variants, 46 (41%) had either the p.N235S (27 out of 111, 24%) or the p.R290H (19 out of 111; 17%), both classified as LP (Supp . Table S1 ).
Prevalence of potentially pathogenic TP53 variants in the FLOSSIES database
A total of 45 unique TP53 variants with MAF < 1% were detected in the FLOSSIES database (N = 9,884), including 26 non-synonymous and 19
synonymous. From these, 1 was classified as P, 7 as LP, 7 as PP, 27 as LB, and 3 as VUS. The frequency of P variants only, and in combination with LP, ranged from 0.01% to 0.17% (Table 2) . Seventeen individuals were detected with potentially pathogenic variants. Among them, seven carried the p.R290H (seven out of 17; 41%) and four carried the p.N235S
(four out of 17, 23.5%) variants, both classified as LP (Supp. Table S1 ).
Prevalence of potentially pathogenic TP53 variants in the WES Controls database
We also queried our in-house WES Controls data of cancer-free individuals (N = 994). A total of seven unique variants with MAF < 1%
were detected, including six non-synonymous and one synonymous.
One variant was classified as P, 2 as LP, 1 as PP, 3 as LB, and none was VUS. Based on the respective allele count values for P variants only, and in combination with LP, the prevalence of germline TP53 variants ranged from 0.1% to 0.3% (Table 2 ). There were no allele count enrichments for specific variants within this cohort (Supp . Table S1 ). Figure 2 and Supp. Table S2 show the distribution of the variants detected in all three databases across TP53 protein domains. Thirteen non-synonymous and 13 synonymous variants were detected in more than one database, including three that were observed in all three databases; therefore, after excluding duplicates, we evaluated a total of 165 unique variants. For potentially pathogenic variants, 28 out of 34 (82%) fall within the DNA binding domain, two in the oligomerization domain, two in DNA-binding and oligomerization domains transition region, one in the proline-rich domain, and one in the C-terminal regulatory domain.
Distribution of TP53 variants across p53 protein domains
Distribution of TP53 variants across different ethnic groups
The distribution of variants across different population ancestries are shown in Supp. . Table S1 ). In addition, the population of African American ancestry had a higher proportion of PP variants (Supp . Table S3 ), primarily due to the presence of the p.Y107H variant in six individuals (Supp. Table S1 ).
No ancestry comparison was performed among individuals from our in-house WES Controls database since all of them had European ancestry (Supp . Table S3 ).
DISCUSSION
LFS has been considered a rare highly penetrant multi-cancer predisposition syndrome (Bougeard et al., 2015) . The criteria for identifying LFS are summarized in the "Revised Chompret criteria" developed by the French LFS working group (Bougeard et al., 2015) , which considers four typical familial or individual presentations suggestive of LFS. Germline variants in the TP53 gene are the only unequivocally identified genetic alterations underlying LFS. These variants may be detected in about 30% of the subjects meeting the Revised Chompret criteria and in about 80% of the families with the most severe clinical patterns of LFS (Mai et al., 2012) . To date, estimates of the prevalence of germline TP53 variants in the general population have been based on small-scale studies and our current understanding of LFS may be biased due to preferential ascertainment of highly affected LFS families, and/or individuals with multiple early cancers. The first published population frequency estimate of 1:5,000 was based on a cohort selected for personal early-breast cancer history (Lalloo et al., 2003) , whereas the second estimate of 1:20,000 consisted of 341 clinically categorized families, of which 296 (87%) met any LFS or Li-Fraumeni-like criteria established at the time of the study (Gonzalez et al., 2009 (Kim, Field, Schultz, Hill, & Stewart, 2017) .
The presence of undiagnosed adult carriers with potentially pathogenic TP53 variants mostly in the DNA binding and oligomerization domains, the TP53 hotspot regions Hainaut & Pfeifer, 2016) , raises the question of whether all germline potentially pathogenic TP53 variants confer a diagnosis of LFS. This is further illus- Another lesson from this large-scale analysis of sequencing databases is that potentially pathogenic variants might be present in subjects and families who may not carry an increased risk of developing cancer as compared with non-carriers. This situation has been well demonstrated in the case of the TP53 p.R337H variant, which is common in the Brazilian population (Achatz et al., 2007) due to a founder effect (Pinto et al., 2004; Garritano et al., 2010) . This variant carries an individual cancer risk which is extremely variable, from fully penetrant LFS to cancer-free over a lifetime (Achatz & Zambetti, 2016) , suggesting that additional components may regulate its penetrance. Among these factors, we and others have provided evidences that intragenic TP53 polymorphisms or MDM2 could modulate penetrance and age at cancer diagnosis in LFS (Bougeard et al., 2006; Marcel et al., 2009 (Bouaoun et al., 2016) .
However, the two most common variants in our analysis, p.R290H and p.N235S, have less certain pathogenic significance (see Supp. Information for further details). The high representation of these two variants in sequencing databases of individuals unselected for cancer risk calls for caution in interpreting them as causal for LFS when detected in a familial setting.
Although TP53 is one of the most widely studied genes, the prediction of deleteriousness by the current annotation tools still needs to be refined. Variants in TP53 should be interpreted not solely based on structure/function prediction algorithms but also considering the cumulative knowledge of clinical outcomes and functional assays in experimental systems. Variants may affect p53 functionality in many ways and a number of variants predicted to be likely benign, or with uncertain significance, may exert a detrimental effect through other mechanisms based on the nature of the amino-acid substitution, such as aberrant splicing. Furthermore, even some synonymous variants such as p.T125T have been shown to activate aberrant cryptic splicing sites (Varley et al., 2001) and are now considered as potentially pathogenic variants. One of the limitations of this analysis is that we were unable to analyze insertions, deletions, or indels, UTR, and intronic variants, for which current annotation tools are still very imprecise. However, we acknowledge that some variants in these regions may also have a detrimental effect, such as the recently published germline variant (rs78378222) in the TP53 3 ′ UTR region (Macedo et al., 2016) . Therefore, due to conflicting results and limited available data, the variant classification presented herein may change in the near future as collaborative efforts such as the Clinical Genome
Resource (ClinGen) consortium (Rehm et al., 2015) has aimed to provide more comprehensive variant curation guidelines specific for TP53
variants.
While the prevalence of TP53 pathogenic mutations was consistent across the data sources in our study, limitations of the data might affect our ability to infer our results to the general population as we relied predominantly on public genomic datasets with limited phenotype data. We excluded individuals with a known prior history of cancer included in the dataset from the TCGA consortium to avoid variant overrepresentation either due to individuals that were recruited based on cancer history or even blood samples contaminated by circulating tumor cells. Nevertheless, the ExAC database includes both cases and controls for other clinical outcomes that might enrich for variants that are also associated with cancer risk. Also, although the ExAC database restricted inclusion to unrelated adults without severe pediatric diseases, it may still contain cancer-affected individuals or some clinical characteristics that should be excluded depending upon the aim of the analyses (Lek et al., 2016) . Another potential bias that may lead to an overestimation of the true prevalence is the presence of somatic TP53 mutations due to clonal hematopoiesis. In this context, the FLOSSIES and the WES Controls databases would be particularly prone as the prevalence of clonal hematopoiesis has a significant increase after the sixth decade of life (Genovese et al., 2014; Jaiswal et al., 2014) . The FLOSSIES database used an allele fraction cutoff of 0.25; therefore, there may be residual somatic variants whose allele fractions were between 0.25 and the desirable cut-off of 0.3. This 0.3 threshold has been proposed to reduce the proportion of somatic TP53 variants that could be wrongly ascertained as of germline origin (Coffee et al., 2017) . However, prevalence estimates were comparable for the FLOSSIES database and our WES Cohort, which used an allele fraction cut-off of 0.3 and is also mostly comprised by older people, thus results for the FLOSSIES database may not have been substantially impacted (allele fraction cut-off for the ExAC database was not available). On the other hand, the available sequencing data were based primarily on studies that recruited participants in adulthood, excluding all those who may have developed cancer in childhood, a common occurrence in LFS (Bougeard et al., 2015) . This is a potential bias that may lead to an underestimation of the true frequency of pathogenic germline TP53 variants carriers in the general population.
Ultimately, we acknowledge that our findings raise more questions than provide definitive answers. Altogether, additional family studies, functional data, analysis of genetic co-factors, and improved variant curation guidelines are still required to better stratify clinical management of LFS patients.
In summary, our results suggest that the prevalence of pathogenic germline TP53 variants in the population may be substantially higher than previous estimates. This implies that the actual cancer penetrance of LFS may be lower than expected, suggesting that sequencing data and variant curation should be carefully interpreted. We encourage further studies of penetrance modifiers and individuals with TP53 variants to better classify variants with regards to their pathogenicity and enrich knowledge of variant curation for clinical purposes.
